Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 86

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 86
---
 12.2 to approve the compensation for the executive officers. •“FOR” Proposal No. 13 to approve the CVR Agreement. •“FOR” Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Q.What should I do if I receive more than one set of voting materials? With regard to the NLS Meeting, shareholders of NLS which receive more than one set of voting materials are asked to inform NLS and return all redundant voting materials to NLS by mail (NLS Pharmaceutics Ltd., Alexander Zwyer, The Circle6, 8058 Zurich, Switzerland) or e -mail(acz@nls -pharma.com). Shareholders can only cast as many votes at their shareholding at the record date entitle them to. Q.Will the NLS Board and Kadimastem Board obtain a third -party valuation report or fairness opinion in determining whether or not to proceed with the Merger? The Kadimastem Board obtained a fairness opinion and a valuation report relating to the Merger in a form reasonably satisfactory to it. The fairness opinion was not prepared for the benefit of NLS’s shareholders and accordingly, NLS’s shareholders are not entitled to rely on the fairness opinion. Additionally, the fairness opinion does not opine on the fairness of the Exchange Ratio to NLS or NLS’s shareholders. For more information, please see the section entitled “ Fairness Opinions and Valuation Reports of Moore Financial Consulting” in this proxy statement/prospectus. Q.Do I have appraisal rights in connection with the proposed Merger? Holders of NLS Common Shares do not have appraisal rights under the laws of the State of Israel or under the laws of Switzerland in connection with the Merger. Q.Who is paying for this proxy solicitation? NLS will bear the cost of soliciting proxies. In addition to these proxy materials, NLS’s directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. NLS may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners. Q.What will happen to Kadimastem’s equity awards plans? At the Effective Time each option, restricted share unit, restricted share, warrant or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares, shall be assumed by NLS